SPRY ARS Pharmaceuticals PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: SPRY
- PE Ratio
The current P/E ratio of SPRY cannot be calculated, as the latest EPS of -$0.17 is negative. The most recent PE ratio recorded for ARS Pharmaceuticals was 131.88 in December 2024.
SPRY PE ratio history
Over the last four years, the average PE ratio of ARS Pharmaceuticals has been 39.15. Analyzing the last four years, SPRY's PE ratio reached its highest point in the Dec 2024 quarter at 131.88, with a price of $10.55 and an EPS of $0.08. The Sep 2021 quarter saw the lowest point at 0.61, with a price of $9.98 and an EPS of $16.31.
ARS Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 131.88 | N/A | $10.55 | $0.08 |
| 2023 | N/A | N/A | $5.48 | -$0.57 |
| 2022 | N/A | N/A | $8.53 | -$0.87 |
| 2021 | N/A | N/A | $6.66 | -$0.7 |
| 2020 | N/A | N/A | $46.34 | -$11.33 |
| 2019 | N/A | N/A | N/A | -$36.27 |
| 2018 | N/A | N/A | N/A | -$29.11 |
ARS Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | N/A | N/A | $12.58 | -$0.17 |
| Dec 2024 | 131.88 | N/A | $10.55 | $0.08 |
| Sep 2024 | N/A | N/A | $14.5 | -$0.51 |
| Jun 2024 | N/A | N/A | $8.51 | -$0.47 |
| Mar 2024 | N/A | N/A | $10.22 | -$0.52 |
| Dec 2023 | N/A | N/A | $5.48 | -$0.57 |
| Sep 2023 | N/A | N/A | $3.78 | -$0.71 |
| Jun 2023 | N/A | N/A | $6.7 | -$0.76 |
| Mar 2023 | N/A | N/A | $6.51 | -$0.79 |
| Dec 2022 | N/A | N/A | $8.53 | -$0.87 |
| Sep 2022 | 9.96 | -78.86% | $5.28 | $0.53 |
| Jun 2022 | 47.11 | N/A | $4.24 | $0.09 |
| Mar 2022 | N/A | N/A | $3.51 | -$0.4 |
| Dec 2021 | N/A | N/A | $6.66 | -$0.7 |
| Sep 2021 | 0.61 | -90.15% | $9.98 | $16.31 |
SPRY Price vs fair value
SPRY average PE ratio chart
SPRY PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $288.74M |
| OMER Omeros Corp | N/A | $195.7M |
| VIVS VivoSim Labs Inc. | N/A | $2.66M |
| ORIC Oric Pharmaceuticals Inc | N/A | $645.48M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $93.14M |
| SPRY ARS Pharmaceuticals Inc | N/A | $1.36B |
Frequently asked questions
What is ARS Pharmaceuticals's PE ratio?
The current price to earnings ratio of SPRY cannot be determined, as its EPS of -$0.17 is negative.
What is the highest PE ratio for SPRY?
Over the last four years, the Dec 2024 quarter recorded the highest quarterly PE ratio at 131.88.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.